This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: AbbVie, Cerevel Therapeutics could point to fragmented markets, different mechanisms of action for overlapping drugs

By Flavia Fortes ( January 24, 2024, 20:06 GMT | Comment) -- AbbVie and Cerevel Therapeutics have overlapping drugs in use or in the pipeline that could draw scrutiny from the US Federal Trade Commission in its review of their $8.7 billion deal. However, the parties could point to fragmented markets with numerous alternatives or different mechanisms of action for their drugs to try to avoid in-depth scrutiny next month.AbbVie and Cerevel Therapeutics have overlapping drugs in use or in the pipeline that could draw scrutiny from the US Federal Trade Commission in its review of their $8.7 billion deal....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login